Oxycodone

PBAC's latest decision on Oxycodone: Recommended with restriction (2019). Considered for Acute severe disabling pain unresponsive to non-opioid analgesics for short-term use (2–3 days) in patients with severe disabling pain.

Eligible population

Patients with acute severe disabling pain unresponsive to non-opioid analgesics requiring short-term (2–3 days) pain relief.

Therapy area

Pain

Line of therapy

Any

Evidence base

Cost-minimisation

Primary endpoint

Cost-minimisation

Comparator

oxycodone 5 mg (20 capsules, existing PBS listing)

Economic model

BIA only

ICER note

Not applicable — minor submission for new pack size/maximum quantity with no economic comparison or ICER calculated.

Submission history

• Nov 2014: Noted · Restricted
• Jul 2019: Noted · Authority Required
• Jul 2019: Recommended with restriction · Restricted

Similar precedents

• Oxycodone hydrochloride
  similarity 0.76
• Oxycodone, tramadol, codeine, hydromorphone, morphine, tapentadol, buprenorphine, fentanyl
  similarity 0.76
• Oxycodone with naloxone
  similarity 0.73
• Oxycodone hydrochloride + naloxone hydrochloride
  similarity 0.74
• Buprenorphine
  similarity 0.73
• Buprenorphine; oxycodone + naloxone
  similarity 0.71